Related Experiment Video
Updated: May 31, 2026
Isolation of Glomeruli and In Vivo Labeling of Glomerular Cell Surface Proteins
Published on: January 18, 2019
In vitro removal of beta-2-microglobulin from uremic blood with an immunoadsorption wall
Tsung-Hua Yang1, Bo-Jhou Lin, Yi-Ling Ma
1Department of Chemical and Materials Engineering, Cheng Shiu University, Kaohsiung, Taiwan. thyang@csu.edu.tw
Abstract:
Dialysis-related amyloidosis (DRA), caused by the accumulation of beta-2-microglobulin (β-2M), remains a major concern in long-term renal replacement therapies. For years, we have developed an immunoadsorption wall (iWall) for the removal of β-2M. In this study, we employed a new approach taking advantage of the melting of a buffer ice rod to improve the conditions associated with the manufacturing of an iWall and tested its performance with uremic serum and blood. The preliminary results reveal that the present iWalls thus prepared not only possess the superior properties of affinity and specificity but also show structural stability and acceptable hemocompatibility. We believe that this breakthrough might provide a promising path to successful treatment of DRA as well as establish a useful platform for studying removal of certain pathological toxins accumulated in the blood.
Insights
A new method for manufacturing immunoadsorption walls (iWalls) improves beta-2-microglobulin (β-2M) removal, offering a potential treatment for dialysis-related amyloidosis (DRA). This breakthrough shows promise for managing β-2M accumulation in patients undergoing long-term renal replacement therapy.
Area of Science:
- Biomedical Engineering
- Nephrology
- Materials Science
Background:
- Dialysis-related amyloidosis (DRA) is a complication of long-term renal replacement therapy, caused by beta-2-microglobulin (β-2M) accumulation.
- Current therapies face challenges in effectively removing β-2M.
- Immunoadsorption walls (iWalls) have been developed for β-2M removal.
Purpose of the Study:
- To develop an improved manufacturing method for iWalls.
- To evaluate the performance of iWalls produced using the new method.
- To assess the potential of these iWalls for treating DRA.
Main Methods:
- A novel approach utilizing the melting of a buffer ice rod was employed for iWall manufacturing.
- The performance of the manufactured iWalls was tested using uremic serum and blood.
- Key properties such as affinity, specificity, structural stability, and hemocompatibility were evaluated.
Main Results:
- The new manufacturing method yielded iWalls with superior affinity and specificity for β-2M.
- The iWalls demonstrated good structural stability.
- Acceptable hemocompatibility was observed in preliminary tests.
- The iWalls effectively removed β-2M from uremic serum and blood.
Conclusions:
- The improved iWall manufacturing process offers a promising strategy for the treatment of dialysis-related amyloidosis.
- This approach provides a viable platform for the removal of pathological toxins like β-2M from the blood.
- Further research may establish this as a significant advancement in managing DRA and related conditions.
Related Concept Videos
01:25Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy